Skip to main content
. 2022 Dec 14;13:1068091. doi: 10.3389/fimmu.2022.1068091

Figure 2.

Figure 2

Ex-vivo treatment with nivolumab of 3D PDE in RCCS Bioreactor. (A) Heatmap showing gene expression levels in MM PDE deriving from lymph node metastases of treatment-naïve melanoma patients. Ratio of PDE treated with nivolumab and untreated control, p=0.013 by MANOVA. *: patients responding to adjuvant immunotherapy (absence of relapse at one year). (B) IHC staining of CD3, Granzyme B and ki67 in a representative case of MM PDE. Ctr: Control; +nivo: +nivolumab. (C) Granzyme B, CX3CL1 and IL8 in culture supernatants from MM PDE. (D) Expression of IFNG, Granzyme B (GZMB) and TNFA transcripts in PDE from STS after treatment compared to untreated control by qRT-PCR. p < 0.05 by paired Student’s t test. RE, Relative Expression. -, untreated control; +, nivolumab.